3 Stocks Pulling The Health Care Sector Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 56 points (0.3%) at 17,533 as of Monday, Aug. 17, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,658 issues advancing vs. 1,301 declining with 196 unchanged.

The Health Care sector currently sits up 1.1% versus the S&P 500, which is up 0.3%. A company within the sector that fell today was Shire ( SHPG), up 1.3%. Top gainers within the sector include Parexel International ( PRXL), up 8.4%, Centene ( CNC), up 2.8%, Alnylam Pharmaceuticals ( ALNY), up 2.5%, Aetna ( AET), up 1.9% and St Jude Medical ( STJ), up 1.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Care sector lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $0.47 (-1.1%) to $40.68 on average volume. Thus far, 86,650 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 177,600 shares. The stock has ranged in price between $40.26-$40.72 after having opened the day at $40.34 as compared to the previous trading day's close of $41.15.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. Fresenius Medical Care AG & Co. KGaA has a market cap of $25.5 billion and is part of the health services industry. Shares are up 10.8% year-to-date as of the close of trading on Friday. Currently there are 2 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Icon ( ICLR) is down $3.10 (-3.8%) to $79.21 on heavy volume. Thus far, 1.5 million shares of Icon exchanged hands as compared to its average daily volume of 528,600 shares. The stock has ranged in price between $77.84-$81.32 after having opened the day at $80.18 as compared to the previous trading day's close of $82.31.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. Icon has a market cap of $4.9 billion and is part of the health services industry. Shares are up 61.4% year-to-date as of the close of trading on Friday. Currently there are 6 analysts that rate Icon a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Icon as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Icon Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $3.70 (-0.6%) to $572.60 on light volume. Thus far, 152,170 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 717,700 shares. The stock has ranged in price between $571.59-$577.46 after having opened the day at $574.73 as compared to the previous trading day's close of $576.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $58.4 billion and is part of the drugs industry. Shares are up 40.5% year-to-date as of the close of trading on Friday. Currently there are 12 analysts that rate Regeneron Pharmaceuticals a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, solid stock price performance and growth in earnings per share. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices